acute ischaemic stroke patients suitable for recombinant tissue plasminogen activator (rt-PA) treatment, MR is the gold standard imaging for visualization in vivo of SVD. MR imaging phenotype of SVD ranges from white matter changes (WMCs) to enlarged perivascular spaces (EPVS), 3 and MR is the first choice for imaging in non-acute stroke setting.
A growing body of evidence, mostly from CT-based studies, focusses on the effect of a single feature of SVD (eg leukoaraiosis) on acute stroke treatment. Leukoaraiosis, the most extensively studied SVD feature in relation to acute ischaemic stroke and rt-PA treatment, has been related to an increased risk of symptomatic intracerebral haemorrhagic transformation [4] [5] [6] and worse clinical outcomes. [7] [8] [9] However, SVD is a heterogeneous process with a various imaging phenotype, and little is known about whether combinations of preexisting imaging features can better convey predictive information on relevant outcomes. Staals et al. recently proposed a score 8, 9 to assess the global burden of SVD, introducing the concept that the whole spectrum of modifications rather than the single feature of SVD may provide valuable information for patients. Their score has been tested in a non-acute stroke scenario with MR assessment of SVD.
The global assessment of SVD burden among acute stroke pa-
tients has been only partly tested in one study. In a cohort of patients treated with rt-PA, leukoaraiosis did not affect subsequent functional outcome, and only lacunes were associated with death 4. However, a re-analysis of the same dataset considering leukoaraiosis and lacunes as a combined score showed an independent association with both poor functional outcomes and symptomatic intracerebral haemorrhage after rt-PA. 7 In the present study, we aimed to explore the relationship between single and combined imaging findings of SVD and clinical outcomes in a cohort of patients with ischaemic stroke and available MR imaging before rt-PA treatment. and severe brain atrophy, either central or cortical (≥2). The combined four-point ordinal score assessed the global burden of SVD from 0 (no imaging features of severe SVD) to 3 (imaging features of SVD scored as severe for each imaging variable).
| METHODS
Our main outcome was the modified Rankin Scale (mRS) recorded 90 days after the index stroke. We considered mRS as ordinal scale (0-1=excellent outcome, 2-3=good outcome, 4-5=bad outcome, 6=death) and as dichotomous outcome (0-1 vs 2-6=disability/death; 0-2 vs 3-6=functional dependence/death; 6=death within 3 months).
| Statistical analysis
We described general characteristics of the study population using basic descriptive statistics as appropriate. Our explanatory variables were each imaging feature of SVD and the SVD score. We run univariate analysis and retain variables with P<.1 in multivariate models.
To assess independent associations, we adjusted univariate analysis for age, sex, NIHSS, OTT in both logistic and ordinal regression analysis. We considered P value<.05 as statistically significant. Statistical analysis was carried out using SPSS for Windows (version 22.0; SPSS, Armonk NY, IBM Corp.).
| RESULTS
A total of 269 patients had available baseline MR scans. Ten scans were excluded for poor quality (movement artefacts and absence of relevant sequences); therefore, 259 patients had scans available to assess white matter changes, brain atrophy and lacunes, whereas 164 patients had available T2 axial section to assess EPVS. Baseline characteristics of study population are shown in P=.002). There were no other differences with regard to relevant clinical variables (Table S1 ). After 3 months from the index stroke, 90 (60%) patients had a mRS=2-6 (disability/death); 77 (51%) patients had a mRS=3-6 (functional dependency/death); 41 patients (27%) died (mRS=6). Although not statistically significant, we found the same direction of association in patients with moderate-severe (grade 2 and 3) SVD score (OR=1.94; 95% CI=0.92-4.09; P=.087) (Figure 2 ).
| DISCUSSION
We found that in a small cohort of ischaemic stroke patients treated with IV rt-PA, severe preexisting WMCs were associated with increased odds of poor clinical outcome. Global burden of SVD quantified with a combined score was also associated with disability and functional dependency. Lacunes, brain atrophy and EPVS showed no association with relevant clinical outcomes.
Our findings regarding WMCs are in keeping with previous larger studies that showed a negative association between WMCs grade and clinical outcomes. 8, 9 We built on these studies by applying the gold standard tool for detection of SVD features 3 (ie MR) and confirmed the effect of WMCs on outcome on a smaller dataset. As a common imaging marker of SVD, WMCs could affect stroke outcomes through various mechanisms. In the hyperacute phase of ischaemic stroke, WMCs may influence the infarct volume and are associated with a larger growth of the infarct size. [14] [15] [16] WMCs are also associated with larger cortical infarcts after distal arterial occlusion, 13 suggesting that microcirculation could be affected also in the grey matter and therefore lead to greater cerebral damage. Patients with WMCs display reduced vascular density, 17 impaired cerebral perfusion 18 and SVD is related to both endothelial dysfunction and blood brain barrier leakage, which are thought to be key drivers of its pathophysiology. [19] [20] [21] Furthermore, rheological modifications such as increased platelet activation 22 and a pro-coagulative status may occur together with SVD. 23 Each of the aforementioned physiopathological processes related to SVD may eventually result in a larger infarct size, impaired reperfusion after recanalization therapy and, from a clinical point of view, in worse outcomes after stroke.
Although our study sample was smaller than previous studies, 8, 9 we found statistically significant associations. Compared to plain CT scan, MR is more sensitive in detection of WMCs; 10, 24 hence, it is reasonable that larger sample sizes are required to reach significant results when using CT, particularly regarding the evaluation of WMCs.
On the other hand, agreement of visual rating scales for WMCs between MR and CT is fairly good, 25 and both WMCs and brain atrophy scales have been validated for MR and CT. 8, 10 Conversely to a previous larger study, 4 we did not found any independent association between lacunes and clinical outcomes. The sample size and the consequent lack of adequate statistical power may be the reason for this discrepancy.
We also investigated EPVS in relation to acute stroke outcomes.
EPVS are an imaging hallmark of SVD and have been associated with cognitive decline after stroke. 26, 27 We found EPVS common in patients with stroke, and their relation with clinical outcomes may be of clinical interest. We found a significant association with poor outcomes in the univariate analysis; however, our study was likely underpowered to demonstrate an independent association after multivariable adjustment. Future studies may specifically address whether EPVS have a predictive role in stroke outcome and in patients treated with rt-PA or mechanical thrombectomy.
SVD features frequently occur together, and we tried to quantify the cumulative effect of combined signs. Considerably, we found signs of two or more severe SVD features in around one-third of our patients, and this negatively affected clinical outcomes. Therefore, we
showed that quantification of global burden of SVD is feasible and has clinical relevance, as previously suggested by other groups.
28,29
We did not assess the entire imaging phenotype of SVD detectable with MR; rather, we chose features visible with both MR and plain CT scan to enhance the feasibility of use in clinical practice. We observed a meaningful association between the SVD score and clinical outcomes, with WMCs acting as the driving feature for poor outcome.
We acknowledge that the SVD score requires further validation with larger sample size in acute stroke setting and with CT scan evaluation of SVD features. However, if validated, the score might be applied in both clinical practice and clinical trials and increase the power to predict outcomes. Moreover, in an acute stroke scenario, the use of the SVD score may redress CT limitations in the detection of single SVD features and provide more accurate estimates about stroke prognosis.
The strengths of our study include the blinded rating of SVD features, the use of the gold standard for SVD assessment in vivo (ie MR imaging) and the qualitative rating of SVD features with extensively validated scales, easily transferrable to clinical practice. The small sample size is the main limitation of our study, and we recognize that our results related to the SVD score need external validation in larger cohorts. Another limit is the number (almost a half) of patients with missed outcomes at follow-up. Assuming that missed patients generally face worse outcomes compared to non-missed patients, one could argue that our patients with available outcomes had a milder stroke profile. However, the comparison of baseline characteristics of included and excluded patients does not seem to support this attrition bias. In fact, stroke severity and OTT, two of the most important predictors of unfavourable outcomes, were higher (ie increased odds of poor outcome) in the population with available outcomes at follow-up.
In conclusion, we showed that in a cohort of MR-based imaging patients with acute ischaemic stroke treated with IV rt-PA, WMCs are frequent and associated with disability, functional dependency and a shift towards worse outcomes in ordinal analysis. We also utilized a combined score that takes into account preexisting global burden of SVD radiological features and found the score associated with disability and functional dependency. The SVD score is potentially feasible for application in an acute stroke setting, and after validation for CT scan could inform the risk of attaining a poorer outcome after rt-PA treatment, particularly in patients with two or more signs of severe SVD; this may also inform the design of future clinical trials. Our results lend support to the theory that SVD may act as a marker of brain frailty; the presence of SVD, and particularly WMCs, has negative effects on clinical outcomes. 
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